Key takeaways
- Retatrutide is a triple-receptor agonist that activates the GIP, GLP-1, and glucagon pathways at once, a more comprehensive approach than the single-pathway weight-loss drugs most people know.
- Phase 2 trials are striking: a 12mg arm averaged -24.2% body weight at 48 weeks versus -2.1% on placebo, alongside meaningful HbA1c and liver-fat reductions.
- Beyond weight, trials report better blood-sugar control and large reductions in liver fat, which is why retatrutide is being studied across several metabolic conditions.
- A large phase 3 program (the TRIUMPH trials), including a cardiovascular and kidney outcomes study, is now underway to confirm and extend these findings.
- Weight loss includes both fat and lean mass, which is why physician oversight and attention to body composition matter.
What is retatrutide?
Retatrutide is a once-weekly injectable being developed for obesity and related metabolic conditions. It belongs to the same broad family as well-known incretin medications, but it is distinctive because it acts on three hormone pathways at once rather than one or two.
It is still in clinical development. The most robust results so far come from phase 2 trials, and a large phase 3 program is now underway to confirm them. In short: promising early data, with large-scale research still in progress.
How it works
Retatrutide is described as a triple-hormone-receptor agonist, meaning it activates the receptors for three gut and metabolic hormones: GIP, GLP-1, and glucagon. GLP-1 and GIP receptor activity is associated with reduced appetite, slower gastric emptying, and improved insulin response, mechanisms shared with existing incretin therapies.
The addition of glucagon receptor activity is what sets retatrutide apart. Glucagon signaling is thought to influence energy expenditure and liver fat metabolism. In theory, combining all three pathways could amplify the effects on body weight and on fat stored in the liver. The trials below test whether that combined design delivers the expected weight and liver-fat effects.
What the phase 2 trials found
The human evidence is early but striking. In a 2023 phase 2 randomized controlled trial in adults with obesity (338 participants over 48 weeks, published in the New England Journal of Medicine), the 12mg dose arm achieved a mean body-weight reduction of 24.2% compared with 2.1% on placebo. That is a large effect, though phase 2 trials are small and short.
A separate 2023 phase 2 trial in people with type 2 diabetes, published in The Lancet, reported dose-dependent reductions in HbA1c (a marker of blood sugar control) and in body weight, compared with both placebo and the active comparator dulaglutide. A 2024 phase 2a trial in Nature Medicine examined metabolic dysfunction-associated steatotic liver disease (MASLD, or fatty liver) and found markedly reduced liver fat. Most recently, a 2025 analysis in The Lancet Diabetes and Endocrinology looked specifically at body composition in people with type 2 diabetes, quantifying how much of the weight change came from fat mass versus lean mass.
Taken together, these are consistent signals across several metabolic conditions, all from phase 2 testing. A phase 3 program is now studying retatrutide in much larger groups, including a roughly 10,000-person trial of cardiovascular and kidney outcomes. Those results will confirm the benefits and characterize long-term safety before firm conclusions about everyday clinical use can be drawn.
What it is being explored for
Based on the published research, retatrutide is being studied chiefly for obesity, for type 2 diabetes and blood-sugar control, and for fatty liver disease. The body-composition data are a useful reminder that significant weight loss involves losing both fat and lean tissue, which is one reason medical supervision, monitoring, and attention to protein intake and resistance training are commonly emphasized in metabolic care.
Whether retatrutide is appropriate for any individual is a question for a qualified physician after a full assessment.
The evidence
Selected references, each verified against primary sources (PubMed and ClinicalTrials.gov). Explore the full, filterable research library on our Science page.
This article is for educational purposes only and is not medical advice, a diagnosis, or a treatment recommendation. Retatrutide is discussed in the context of the published research; inclusion of a study does not imply a guaranteed outcome. Many of these compounds are investigational and not approved for the uses described in all jurisdictions. Any treatment decision should be made with a qualified physician. Individual results vary.